Savara, Inc. · NASDAQ:SVRA
Savara — Investor Presentation (October 2025)
15 slides from Savara's investor presentation, Oct 29, 2025
Slide 1: Corporate Overview October 2025
Corporate Overview October 2025 © Savara Inc. All Rights Reserved. Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “pla
Slide 3: Sizeable U.S. Market Opportunity for MOLBREEVI in Autoimmune PAP
Sizeable U.S. Market Opportunity for MOLBREEVI* in Autoimmune PAP MOLBREEVI has the potential to be the first FDA approved treatment for this chronic disease © Savara Inc. All Rights Reserved. Current U.S. TAM1 of autoimmune pulmonary alveolar proteinosis (autoimmune PAP) patients >$2B Potential U.S
Slide 4: Overview of Royalty Financing with RTW
Overview of Royalty Financing with RTW © Savara Inc. All Rights Reserved. $75M non-dilutive strategic financing from RTW for MOLBREEVI Funded upon FDA approval, subject to satisfaction of customary closing conditions Tiered royalty payments, based on U.S. net sales thresholds, range from 7% initiall
Slide 5: Autoimmune PAP: Disease of Alveolar Macrophage Dysfunction
Autoimmune PAP: Disease of Alveolar Macrophage Dysfunction © Savara Inc. All Rights Reserved. Alveoli need surfactant to keep from collapsing GM-CSF is critical for alveolar macrophage function and allows for alveolar surfactant homeostasis, structure, function, and host defense NORMAL vs ABNORMAL A
Slide 6: Current Treatment Option for Autoimmune PAP: Whole Lung Lavage (WLL)
Requires insertion of double-lumen endobronchial tube for lung separation Treated lung is repeatedly filled with up to 15-50L of saline and then drained by gravity Patient is percussed to emulsify the surfactant sediment Saline is drained by gravity and continued until lavage fluid becomes clear A L
Slide 7: IMPALA-2 Results Summary
Largest controlled trial of inhaled GM-CSF therapy for aPAP ever conducted Improvement in DLco% demonstrated: Primary endpoint was change from baseline to Week 24 in DLco% (p=0.0007)1 Achieved improvement in multiple secondary and exploratory end points Pulmonary gas exchange: Change from baseline t
Slide 8: IMPALA-2 Safety Summary: MOLBREEVI Was Well-Tolerated
IMPALA-2 Safety Summary: MOLBREEVI Was Well-Tolerated © Savara Inc. All Rights Reserved. 1SAE of delusions resulting in psychiatric hospitalization in patient with a past medical history of seizure disorder treated with levetiracetam; the event was assessed as possibly related to study drug by the i
Slide 9: Planned U.S. and European Regulatory Timeline
Planned U.S. and European Regulatory Timeline US Started BLA Rolling Submission EU Completed BLALA Submission BLA Resubmission with Fuji as DS Manufacturer Potential Approval* MAA Submission Potential Approval © Savara Inc. All Rights Reserved. *Assumes Priority Review is granted by the FDA. All app
Slide 10: Autoimmune PAP Disease State Awareness Campaign
Autoimmune PAP Disease State Awareness Campaign Multi-channel effort across healthcare professionals (HCP) and patients © Savara Inc. All Rights Reserved. HCP Disease State Awareness Campaign Patient DSA Campaign
Slide 11: aPAP ClearPath: No Charge Third-Party Testing Program in the U.S.
aPAP ClearPath: No Charge Third-Party Testing Program in the U.S.* © Savara Inc. All Rights Reserved. Launched March 2025 Simple finger prick performed in a physician’s office Removes logistical challenges to serum testing ILD program to be expanded, leveraging DBS test** SERUM TEST Launched Decembe
Slide 12: 2025 U.S. Claims Data Analysis Indicates Autoimmune PAP Market is ~50% Larger
2025 U.S. Claims Data Analysis Indicates Autoimmune PAP Market is ~50% Larger than Previously Projected © Savara Inc. All Rights Reserved. * Reporting Period 2008-2023; Patient Stabilization Period (3/1/2021 - 2/28/2023), projected ** Reporting Period: 2017-2025; Patient Stabilization Period (1/1/20
Slide 13: U.S. Centers Prioritized Based on Autoimmune PAP Experience
U.S. Centers Prioritized Based on Autoimmune PAP Experience Goal: Line of Sight to 1,000 Patients at Launch to Maximize Early Launch Phase © Savara Inc. All Rights Reserved. COEs† ILD Centers* General Pulmonary Centers U.S. PATIENTS / HCP HEAT MAP1 1 Data from 2023 U.S. Insurance Claims Analysis con
Slide 14: Overwhelming Support for MOLBREEVI Across Stakeholders
Overwhelming Support for MOLBREEVI Across Stakeholders © Savara Inc. All Rights Reserved. U.S. PATIENTS U.S. PULMONOLOGISTS 83% Likely to prescribe MOLBREEVI regardless of severity of disease Perceived MOLBREEVI as superior to current options based on: Overall efficacy Simple, standard nebulizer Fav
Slide 15: Thank You
THANK YOU © Savara Inc. All Rights Reserved.